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Summary: 
Mortality and morbidity is significantly higher in rural and regional areas due to various factors including  a deficiency in the 
availability of specialist care leading to later diagnosis and delays in treatment. Telemedicine attempts to address some of these 
issues. The main fields that deliver medical therapies through real time videoconference (VC) are oncology for chemotherapy, 
neurology for stroke thrombolysis and nephrology in supervising haemodialysis (HD). This review studies the effectiveness of 
these telemedicine models in terms of patient outcomes and satisfaction.  This systematic review involved a search of 
MEDLINE, CINAHL and INFORMIT databases using key terms. 563 articles on telemedicine were found; from these 67 full 
texts were perused yielding 8 articles for telestroke, 3 for telenephrology and 2 for teleoncology.  Observational studies 
conducted in the field of telestroke have shown favourable outcomes when comparing face to face and VC aided thrombolysis 
with no significant disparity between survival and intra-cerebral bleeds between the two cohorts. HD supervised through VC also 
showed no change in  patient outcomes when compared to HD at dialysis centers. Evidence regarding the efficacy of using real 
time VC for infusion delivery is however limited. Administering active therapeutic interventions seems feasible given the 
presence of certain factors at the rural sites such as CT scanning facilities for stroke management, chemo-competent nurses to 
deliver chemotherapy and dialysis nurses. 
Keywords: telemedicine, videoconference, stroke, thrombolysis, chemotherapy, oncology, renal, dialysis. 
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Introduction 
Cancer is responsible for about 29% of all deaths in Australia and up to 25% of excess deaths in regional areas. In 
regional areas death rates are 10% higher for males and about 5% higher for females than in major cities.(1) Such disparity in 
health outcomes for cancer  between urban and regional populations can be attributed to  later date of diagnosis, poorer access to 
health care, different health seeking behaviour, health workforce shortages in regional areas (especially amongst specialists) and 
higher Indigenous population.(1) Cancer risk factors such as smoking, obesity and alcohol consumption are also higher in rural 
and regional populations.(2) 
To overcome barriers and improve access to oncology treatments various models have been instigated in regional and 
rural  areas, such as face to face outreach clinics or more recently telehealth models.(3) One of the longest running teleoncology 
services, first established in 1995, is in Kansas. This has demonstrated success by incorporating more rural sites under its service 
and also reducing the cost of delivery.(4) Teleoncology has also secured its roots in nations such as Canada, UK and Scotland 
where health resources are concentrated in major cities but the  population is dispersed over a large area.(5, 6) Many existing 
telehealth models across Australia and other developed nations have focused on providing consultations and follow up for their 
regional and rural patients, where most patients continue to travel to larger centers for treatment. Few medical specialties have 
embarked on remotely supervising active medical therapies via Real Time (RT) videoconference (VC) to provide a more 
comprehensive service closer to home. Stroke, cancer and kidney disease management are areas where telemedicine has 
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progressed to supervising active treatment through providing thrombolysis, chemotherapy and dialysis via VC.  Thus, this review 
will aim to explore the outcomes of using telemedicine supervision to deliver active therapeutic treatment to rural patients in the 
fields of stroke, medical oncology and nephrology (widely known as telestroke, teleoncology and telenephrology respectively).  
 
Methods 
 A systematic review was conducted applying the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines.(7) Computerised literature searches were performed using the terms telemedicine AND oncology, 
telemedicine AND “medical oncology” and telemedicine AND stroke, telemedicine AND renal or kidney/s or dialysis with 
language restricted to English. These searches were performed on MEDLINE, Cumulative index of nursing and allied health 
literature (CINAHL) and INFORMIT databases. Some articles were also identified by reviewing the bibliographies and search 
terms of selected articles.  
 Inclusion criteria were the following: articles that utilised models of telehealth to actively deliver treatment to rural, 
regional or remote patients as chemotherapy, thrombolytic infusions or dialysis (as these were three major areas where 
therapeutic interventions have begun to be administered by VC as determined by prior preliminary searching of MEDLINE and 
expert advice from consultants within the fields). Articles also had to assess patient outcomes and/or satisfaction from delivering 
therapeutic infusions via telemedicine in a scientifically valid manner. In addition studies were required to clearly explain the 
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models used to deliver the treatment. Only observational studies and randomised controlled trials would be included in an 
attempt to ensure the assessment of patient outcomes was objective. 
 The exclusion criteria required rejection of articles that solely described the various telemedicine models, their 
description and details about technical feasibility. Articles that utilised telemedicine for consultations, follow-up clinics or 
specialist reviews and did not include providing treatment were excluded. Telemedicine for follow-up appointments after 
provision of thrombolysis, chemotherapy or pre/post dialysis was also excluded. Telepsychology and telerehabilitation of cancer 
and stroke patients were excluded. Letters, conference proceedings, editorials were also excluded.    
 Initial screening of articles was based on review of their titles followed by abstracts. All abstracts were read by the 
primary author independently, and selection of relevant articles relied on the abstracts fulfilling the inclusion criteria. Full length 
articles within the last 15 years were then perused to assess for eligibility according to the inclusion and exclusion criteria. Final 
articles were selected in accordance and after formal meeting with the supervising author and consultant. Data extraction forms 
and tables were developed and data was extracted and reviewed by three authors.  Critical assessment of possible sources of bias 
and confounding in the studies was undertaken. Study results and effect sizes were also extracted and compared where possible.  
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Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database searching for 
all MESH terms 
(n =521;TS n=383, TO n=5, TN n= 133) 
Records identified through other sources 
and search of references  
(n = 42; for TS) 
Records after duplicates removed  
(n = 563) 
Articles excluded 
 (n= 394 for TS, n= 100 for TN, n=2 for TO) 
 
Full-text articles assessed 
for eligibility  
(TS n =31, TN= 33, TO=3) 
Studies included in qualitative synthesis  
(n = 9 for TS, n= 3 for TN, n=2 for TO) 
Full-text articles excluded, with reasons  
(n = 22 for TS; n= 30 for TN, n=1 for TO) 
Records screened at 
abstract level  
(n = 234) 
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Figure 1: The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) flow diagram.(7) TS= 
telestroke, TO= teleoncology, TN= telenephrology 
 
521 articles dealing with all forms of telemedicine were found on MEDLINE of which 394 articles included telestroke 
and all forms of stroke diagnosis, evaluation, investigation and management via telemedicine. 394 abstracts were reviewed from 
which 31 articles were chosen, those excluded either did not utilize telemedicine for direct stroke management or the study 
design was substandard in nature. 31 full texts were perused in detail finally yielding eight articles fit to be included in this 
review. The process is depicted in the flow chart above. 23 articles were excluded due to: 1) lack of administration of therapeutic 
thrombolytic infusion and managing stroke more passively with observation, anti-platelet therapy and other medication regimens 
or 2) articles that focused on stroke rehabilitation and psychosocial therapy or due to 3) limitations in study design including case 
studies, letters and so on.  
The second search was conducted in the field of medical oncology and yielded five articles from which two were chosen 
and three excluded as they did not have appropriate information on patient outcomes or satisfaction rates. From the 133 articles 
identified in telenephrology only 3 met the inclusion criteria and were hence selected for this review.  
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Table 1- Quality Assessment Table-Risk of bias assessment using the Cochrane risk of bias tool (8) 
Bias domains Chowdhury 
2013 (9)  
Zaidi 
2011 (10) 
Johansson 
2011 (11) 
Khan 
2010 (12) 
Audebert 
2006 (13) 
Pedragosa 
2009 (14) 
Meyer 
2008 (15) 
Sairanen 
2011 (16) 
Schwab 
2007 (17) 
Study Design Retrospective 
cohort study 
comparing 
FTF with 
telemedicine 
model. 
Retrospective cohort 
comparison between 
spoke sites and the hub. 
FTF care at hub and  
telemedicine were 
provided by the same 
neurologist 
Retrospective 
cohort 
comparison 
between 
peripheral 
hospitals and 
stroke centre 
Single 
centre case 
series 
Retrospective, 
Comparison of 
outcomes pre 
and post 
implementation 
of telestroke 
services 
Randomised 
controlled study of 
telemedicine vs. 
telephone decision 
making and 
supervision of tPA 
Prospective 
cohort study. 
Comparing 
outcomes at 
community 
hospitals with 
hub 
Prospective 
cohort study. 
Comparing 
outcomes at 
community 
hospitals with 
hub 
Prospective 
cohort study. 
Comparing 
outcome 
between 
regional and 
stroke centres 
Randomisation No No No No No Yes  No No No 
Allocation 
concealment 
No No No No No No Yes No No 
Blinding No No No No No No No No No 
Incomplete 
outcome data 
No No No Yes No No No No No 
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Selective 
outcome 
reporting 
No No No Unclear No No No No No 
Other Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Risk of bias Unclear Unclear Unclear High Low Low Low High Low 
 
Using the Cochrane risk of bias tool, Table 1 depicts that most studies utilized did not undertake randomization, 
allocation concealment or selective outcome reporting making their risk of bias high or unclear. But most, except one study 
satisfactorily reported complete outcome from the data analyzed. From the four out of nine studies that were deemed to be at low 
risk of bias, one was randomised, the other had allocation concealment and all four reported complete patient outcomes. The risk 
of bias from others was high or unclear as they did not fulfill the major criteria. Table 2 summarises the studies selected, their 
study designs and outcomes reported in each study.   
 
 
Table 2: Summary of articles describing the stroke management setting, study design and outcome 
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Reference Country Setting  Study design Interventions 
at remote sites 
Participants Outcomes 
Chowdhury 
2013(9) 
UK Single 
stroke 
centre 
Retrospective 
cohort study  
Evaluation and 
tPA via real 
time VC 
97 patients 
were 
thrombolysed;  
46% were via 
telemedicine 
 
●Intracranial bleed: FTF 7.7% vs.  
telemedicine 4.4% (NS), 
●3 month FO: FTF 36.5% vs. telemedicine 
42%(NS), 
●Process times significantly shorter for face to 
face. E.g. admission to treatment median 
33min vs. 61 min. 
Zaidi 
2011(10)  
USA 12 spoke 
sites and 1 
stroke hub 
 
Retrospective 
cohort  
 
Evaluation and 
tPA via real 
time VC 
Number of 
patients: 
telemedicine 
83, FTF 59, 
 
●3 month FO: 42% vs. 37.5% (NS) 
●No difference in ICB 
●Arrival to treatment: mean 68 min vs. 90 
min(p<0.01), 
●3 month mortality 30% vs. 31%. 
Johannson 
2011 (11) 
Austria Peripheral 
hospitals 
20 -129 km 
away and  
stroke unit 
Retrospective 
cohort  
Evaluation and 
tPA via real 
time VC 
followed by 
transfer to 
stroke unit 
Number of 
patients: 
Periphery 47 , 
stroke centre 
304, 
 
●ICB 6.4% vs. 7.6% (NS), 
●3 months FO 47% vs. 43% (NS), 
●3 month mortality 19% vs. 13% (NS) 
 
Khan 2010 
(12) 
Canada 7 remote 
hospitals 
and 1 hub 
Single centre 
case series 
Evaluation and 
tPA via real 
time VC or 
telephone 
At 2 years, 50 
patients 
received 
telemedicine 
review 
●At 2 years, 50 patients received telemedicine 
review,  
●tPA within 3 hours 73%, 
●ICB 11.4%, 
●3 month mortality 22.5%, 
●3 month FO 40%, 
●92.5% decline in transfer rate. 
Audebert 
2006 (13) 
Germany 12 regional 
clinics and 
2 stroke 
centers 
Prospective 
cohort study, 
 
Evaluation and 
tPA via real 
time VC 
115 at 
community 
hospital versus 
110 at stroke 
●Rate of tPA: community hospitals 
115/4727(2.4%)  and  
Stroke centre 110/1889(5.8%), 
●ICB 7.8% vs. 2.7% (p<0.05), 
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centre ●In hospital mortality 3.5% vs. 4.5 % (NS). 
Pedragosa 
2009 (14) 
Spain Community 
hospitals 
>70 km 
away from 
tertiary 
centre. 
 
Retrospective 
cohort study 
Evaluation and 
tPA via real 
time VC 
Total of 399 
stroke patients 
admitted over 2 
years 
Significant outcomes pre vs post 
implementation: 
(Total of 399 stroke patients admitted over 2 
years). 
●Specialist review 17% vs. 38%, 
●Inter-hospital transfers17% vs. 6%, 
●Rate of tPA 4.5% vs. 9.6%, 
●Time to tPA 210min vs. 162 min, 
●tPA within 3 hours40% vs. 63% 
Meyer 
2008 (15) 
USA 4 remote 
spoke sites 
Randomised 
controlled 
study of 
Telemedicine 
vs. telephone 
decision 
making and 
supervision 
of tPA 
Evaluation and 
tPA via real 
time VC or 
telephone. CT 
images were 
available in the 
telemedicine 
arm; Only 
report was 
available in the 
telephone arm. 
Number of 
patients: 111 in 
telemedicine 
and 111 in 
telephone arms 
●Correct decision making  98% vs. 82% 
(p<0.05), 
●Rate of tPA 28% vs. 23% (NS), 
●90 day FO-no difference 
●90 day mortality19% vs. 13% (NS)  
● ICB7% vs. 8% (NS), 
 
 
 
Sairanen 
2011 (16) 
Finland 5 
community 
hospitals 
130-800 
km away 
and one 
hub 
Prospective 
cohort study, 
 
Evaluation and 
tPA via real 
time VC 
106 patients 
within 5 
community 
hospitals 
●At 2 years, number of patients in community 
hospitals: 106,  
●Rate of tPA 57.5%,  
●ICB 6.7%,  
●3 month mortality 11.5%, 
●3 month FO 49% at spoke sites vs. 58% at 
hub (NS). 
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VC- videoconferencing, tPA-thrombolysis, ICB-intra-cerebral bleed, FTF-face to face care, FO-favourable outcome, NS-not 
significant 
 
 
 
 
 
 
 
Table 3: Summary of articles describing the chemotherapy management setting, study design and 
outcomes 
Schwab 
2007 (17) 
Germany 12 
Community 
hospitals 
vs. 2 stroke 
centres 
Prospective 
cohort study, 
 
Evaluation and 
tPA via real 
time VC 
Over 22 
months, Patient 
number: 
Community 
hospital 170 
and stroke 
centre 132, 
 
●Mortality rate at 3 months 11.2% vs. 11.5%, 
at 6 months 14.2% vs. 13% (NS), 
●FO at 6 months 39.5% vs. 30.9 % (NS). 
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Reference Country Setting Study design Intervention 
at remote 
sites 
Outcomes 
Sabesan 2012 
(3) 
Australia Rural town 
900km away 
from tertiary 
centre 
Single centre 
case series 
Medical 
review and 
supervision of 
chemotherapy 
administration 
via real time 
VC by tertiary 
centre 
 Number of patients 
receiving IVCT 83, 
 No inter-hospital 
transfers after 
teleoncology 
implementation. 
Sabesan 
2012(18) 
Australia Rural town 
900km away 
from tertiary 
centre 
Single centre 
case series-
Questionnaire 
based survey 
of patient 
satisfaction 
As above  Participants 50, 
 96% of patients in 
>80% agreement with 
statement “I am getting 
satisfactory care from 
the specialist on video 
link”. 
VC-videoconferencing, IVCT-intravenous chemotherapy. 
 
 
 
Table 4: Summary of articles on telenephrology: dialysis management setting, study design and outcomes 
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Reference Country Setting Study 
Design 
Intervention Participants Results 
Rygh et al 
2012 (19)   
USA Patients living 
with home 
dialysis 
Qualitative 
using semi-
structured 
interviews 
NA N=11 
patients 
(PD=8, 
HHD=3) 
 Satisfied with home option 
 Continued to require close 
communication and follow up 
 Recognised a need for 
telemedicine models to 
increase independence.  
 
 
Sicotte et 
al  
2011 (20) 
Canada Two James 
Bay Cree 
communities- 
Chisasibi and 
Chibaugamau 
Pre and post 
design 
Tele-HD 
 
N=19 
patients 
(followed for 
12 months 
pre and post) 
 Health outcomes met markers 
from the National Kidney 
Foundation; pre and post. 
 HD sessions= 11.8 pre, 11.1 
post (Chisasibi); 12.5 pre, 12.4 
post (Chibaugamau) 
 Medication changes=8.1 pre, 
3.1 post (Chisasibi);2.2 pre, 
1.8 post (Chibaugamau)  
 Transfers to university 
hospitals=1.1 pre, 1.6 post 
(Chisasibi); 1.3 pre, 1.4 post 
(Chibaugamau) 
Rumpsfeld 
2005 (21) 
Norway University 
hospital of 
north Norway 
and its 2 
satellite sites: 
Alta and 
Hammerfest 
Prospective 
study 
VC for daily 
visits and ward 
rounds. 
9 patients 
followed for 
8 months 
 Technological (28%) and 
logistical (10%) problems 
noted 
 5 hospitalisations and 1/3 of 
planned visiting rounds were 
avoided. 
 Economically non-viable at 
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pilot level: running costs 
higher 
 Nurses reported satisfaction 
with technology and care 
provided. 
NA= not applicable, HHD=home haemodialysis, PD=peritoneal dialysis, VC=Video-conference 
 It is apparent from viewing the tables above that telemedicine has not added to significant adverse outcomes and has 
safely delivered therapies such as thrombolysis, chemotherapy and dialysis to remote patients who would otherwise suffer worse 
health outcomes if they were unable to access these cornerstone treatments. 
 
Discussion 
The quality of most of the studies selected for this review was weak due to lack of randomised controlled trials (RCT) 
and small number of patients. However, given the small number of rural and remote patients and the novelty of the three fields, 
as well as the importance of maintaining patient autonomy around the difficult area of oncology treatments, a RCT may never be 
feasible in many geographically large areas. These studies have used different study designs and comparators. However, all the 
studies reported on similar outcomes and reported side effects, and other outcome parameters like intra-cranial bleeds, arrival 
time to treatment, in-hospital mortality and 3 month mortality rates were consistent across these studies. Though firm 
conclusions cannot be made from these studies, it seems that telestroke and teleoncology for the delivery of active interventions 
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are feasible and safe. Furthermore, it is apparent the real time videoconferencing is preferable to telephone-based systems in 
terms of patient outcomes. 
One limitation in implementing telestroke widely which was identified from the studies is availability of CT scanning 
facilities. Since most rural towns lack this, wide introduction of such models seems unlikely.  
 Chemotherapy administration through telemedicine is a more recent addition to the telemedicine field and thus there has 
not yet been significant literature on the safety and survival of these patients given the novelty of these models. However, 
although it is feasible to remotely supervise many toxic chemotherapy regimens via real time videoconference, the Townsville 
teleoncology model is suited to larger rural centers where there are resident chemotherapy-competent nurses. Therefore patients 
from smaller rural towns continue to travel long distances for their stroke and chemotherapy care. 
To provide access to at least some part of medical therapy closer to homes, new models are required. For example, a remote 
chemotherapy supervision model is currently being trialed at the Townsville Cancer Centre to address this issue. In this model, 
selected chemotherapy regimens are administered by non chemo-competent nurses guided and supervised via real time VC by a 
chemo-competent nurse from TCC.  
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Dialysis too can be adequately provided with guidance from central renal centers. The studies looking at dialysis via VC 
were however scant and reported on various aspects such as economic analysis, hospital transfers and health outcomes and thus 
comparison and solid conclusions cannot be drawn from such one-off studies.   
Within telenephrology, monitoring of rural patients on peritoneal dialysis via VC or mobile phones to address their acute 
complications such as infections with treatment response from urban peritoneal dialysis units has also begun. Although in one 
study this was complimented with n intensive home visit program, the other study used VC as a solitary trouble shooting method 
and monthly evaluations for their rural patients. These studies concentrated more on tele-monitoring as opposed to delivering 
therapies or infusions via VC. (22-24) 
Gallar et al presented the results of home monitoring patients using peritoneal dialysis by installing VC equipment in 
their home and found this a clinically useful model for long term follow up of stable patients minimizing travel, costs and burden 
on patients. Medication changes were undertaken through VC and only 2% of patients required hospital presentation for 
management. In all cases the abdomen was successfully examined for infection or oedema in and around the catheter exit site. 
(25) Two other studies conducted at the same centre in the United States, first looking at health outcome and cost analysis in 
using nursing oversight to conduct telehealth consults with remote patients. This pilot demonstrated improved health outcomes 
and cost benefits. The second larger study looking at 99 patients over 3 years showed again a significant cost benefit with 
decrease in hospitalization and days in hospital; and reduced requirement to conduct telehealth consults with patients taking 
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further ownership of their health. (26, 27) VC is continually being used for clinical consultation required frequently for kidney 
disease patients. (28) 
 
Conclusion 
 Though the quality of the studies are weak, studies from all three fields report outcomes similar to standard practice and 
these models seem both feasible and safe to implement. Current models are suited to larger centers with adequate imaging and 
service capabilities. To provide equitable coverage to most rural patients, new telehealth models and more rigorous studies of 
their effectiveness, acceptability and safety are required.  
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